Biotechnology Businesses for Sale and Investment

R+D and distribution of vegetable seeds. - Exclusivity of highest yielding Roma tomato variety that will change the 12,000 hectares market in Mexico for the next 4-8 years with a potential revenue of US$20-30M per year only for this variety alone. - Great network of suppliers and clients. - There are 20 permanent employees. No additional contract/temporary employees.

Company and product: Enbiosis has developed an advanced artificial intelligence algorithm that analyzes the human gut microbiome and recommends personalized food and supplements to individuals to improve their gut health and address chronic disorders such as gastrointestinal disorders, skin-related disorders, and weight loss issues. - How it works: Patients/customers send their stool samples to any NGS laboratory in their region. Enbiosis takes the raw bacterial DNA data to the local server (to avoid data protection risks) and creates a personalized report, which is sent to patients and, if required, their practitioners within minutes. - Business model: Enbiosis's microbiome test can be sold through practitioners and/or directly to customers, depending on market dynamics. Practitioners can prescribe the test to patients to generate a personalized diet plan, or patients can follow their personalized nutrition guide through the app to improve general well-being and solve their problems. - Main differentiation: Enbiosis is the only clinically proven precision diet technology that claims to address the main cause of chronic disorders. It has conducted three clinical trials and published the results in peer-reviewed journals. Enbiosis's claims are backed by scientific evidence. - The main reason why investors should consider Enbiosis: In recent years, the number of people seeking to address their health problems through alternative methods instead of pharmaceuticals has been increasing. The challenge in alternative medicine is the lack of scientific data. Enbiosis serves as a bridge between alternative medicine and conventional medicine, and there is significant market potential for Enbiosis. For example, Enbiosis has proven the effectiveness of its technology in patients with IBS, who make up about 10% of the population. Offering individuals the opportunity to solve their chronic problems simply by changing their diet within a specific period is something they are interested in and willing to try. - Additionally, investors/distributors can offer a routine follow-up program to check gut health and prevent any kind of diseases, opening the door to long-term recurring revenue. - We have a trade registration certificate to operate.

Offer genetic testing and wellness management services, currently reaching 1,069 customers. - Product development completed, revenue generation started, franchisee appointments, academic programs, and community projects in progress. - Company that provides clients with a vision & understanding of their unique genetic profile and its implication for better wellness. - The field of health genomics has matured in the past two decades and is beginning to deliver genomic-based interventions for health and health care. Every human being will have huge amounts of genetic variation that create the unique individuality seen in a person. - Generate revenue by charging fees for tests to conduct. We charge around INR 20,000-60,000 for consumer genomic tests. - We have 32 employees (lab team, technical team, genetic team, customer support team, and marketing team). - The promoter has 13 years of experience in this industry.

We are a new type of biotech company dedicated to human cancer gene therapy and have been working on research projects and the development of human gene therapy vectors. - Our company has generated various types of DNA nanoparticles for cancer gene therapy. - Now we have developed new type of RNA nanoparticles called engineered cellular microvesicles (ECM), or RNA microvesicles. - These are purified cytomox/anti-cancer gene products, such as p16, p53, PTEN, CDC6 shRNA, purified ECM-RV/anti-cancer mRNA, such as p16, p53, CDC6 shRNA, GSDME, EZH2 shRNA, Klotho, etc. - The technology includes R&D for the above-mentioned particles and products. - The R&D & the technology are valued at USD 1 million. Additionally, USD 3-4 million will be required to complete the clinical trials, tests, and marketing. - The technology is ready and needs to undergo some tests and clinical trials. - We want to sell the technology and help the buyer to get it patented and market the technology.

Our business is a startup company that the first Indian paper-based nano-sensor device, which will detect bacterial infection and antibiotic resistance in 90 minutes. - Company has done 2 and a half years of product research and development before deploying it to Phase 1 testing of product trial and safe use. - Our products are used by our new clients some of which have provided us grants for the phase 2 product developments. - Some of our reputed clients are LG electronic and IIT Delhi, and several hospitals. - We have sold out our products in the last 4 months. - Business has received 4 grants from IIT Delhi, FDI, and many more worth INR 1 crore. - We have medical pieces of equipment which are imported from Germany and Sweden for our medical research and product research. - Our products were first sold for INR 1,200 per 100 ml bottle, but due to the covid situation, we decide to cut the cut to INR 899 per 100 ml bottles. - The promoter has 8 years of experience in the biomedical devices business. - Our business has not taken any kind of business loan and does not have any outstanding balance so far.